BioBridgeX
Log inCompare quotes
IND-Enabling

IND / Regulatory Package Authoring CROs

Free for buyersNeutral vendor of record
Quick answer

IND / Regulatory Package Authoring is the medical and regulatory writing that compiles your nonclinical, CMC, and clinical-plan data into a filing-ready Investigational New Drug (IND) application for the FDA. You need it at the end of the IND-enabling stage, just before first-in-human dosing. On BioBridgeX, buyers source and compare qualified CROs for this work, free, under one contract.

IND / Regulatory Package Authoring CROs on BioBridgeX

We are qualifying and publishing IND / Regulatory Package Authoring CROs now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What is IND / Regulatory Package Authoring and when do you need it?

IND / Regulatory Package Authoring is the regulatory writing and document assembly that turns a pile of study reports into a coherent Investigational New Drug application the FDA can review. By the time you reach this point you have GLP toxicology reports, a CMC package describing how the drug substance and drug product are made and tested, pharmacology data, and a draft Phase 1 protocol. None of that files itself. An authoring CRO writes the integrated summaries that tie it together, drafts the Investigator's Brochure, and assembles everything into the eCTD structure the agency expects.

You need this work at the very end of the IND-enabling stage, after the pivotal studies have read out and before first-in-human dosing. In practice the authoring often runs in parallel with the last few GLP study reports rather than waiting for all of them, because the Module 2 nonclinical overview and summary can be drafted as data lands and finalized once the last report is signed. Treating authoring as an afterthought you start when the science is done is how programs lose four to eight weeks at the finish line, with a dosed clock and a burning runway.

Concretely, the package centers on the Common Technical Document modules: Module 1 (the regional administrative forms, the FDA Form 1571, cover letter, and the proposed clinical protocol), Module 2 (the nonclinical overview and the written and tabulated nonclinical summaries, plus the quality and any clinical overview), Module 3 (the CMC section), Module 4 (the full nonclinical study reports), and Module 5 (clinical, thin at the IND stage). A good authoring partner does not just transcribe data. They build the safety argument that connects your NOAEL and exposure margins to the proposed starting dose, and they flag the gaps a reviewer will catch before the reviewer does.

What does an IND / Regulatory Package Authoring CRO actually do?

The deliverable is a submission-ready dossier, but the work behind it is part medical writing, part regulatory strategy, and part project management across every other vendor on your program. The strongest authoring groups start before the writing does, with a pre-IND meeting strategy: drafting the briefing book, framing the questions you put to the FDA, and shaping the development plan so the eventual filing matches what you agreed with the division. That upstream work often matters more to a clean review than the prose itself.

On the writing side, expect them to own the documents below and to chase the source data, reconcile inconsistencies between study reports, and keep one voice across modules contributed by different specialists.

  • IND assembly and submission: building the eCTD-compliant package, the FDA Form 1571 and 1572s, the cover letter, and the granular table of contents, then publishing and validating the submission for the gateway.
  • Module 2 summaries: the nonclinical overview and the written and tabulated summaries (the 2.6 series) that integrate pharmacology, PK, and toxicology into a single safety narrative.
  • Investigator's Brochure (IB): the clinical reference document that travels to every site and IRB, summarizing what is known about the molecule for the investigators who will dose it.
  • Clinical protocol and informed consent support: regulatory review of the Phase 1 protocol and ICF for consistency with the safety data and the proposed starting dose and escalation scheme.
  • Module 4 organization: compiling and cross-referencing the full GLP nonclinical study reports so they line up with the summaries that cite them.
  • Regulatory strategy and agency interactions: pre-IND briefing books, meeting requests, responses to FDA information requests, and clinical-hold responses if one lands during the 30-day review.
  • Gap analysis: a cold read of the data package against ICH M3(R2) and FDA guidance to find the missing study, the inconsistent number, or the weak justification before submission, not after.

How do you choose an IND / Regulatory Package Authoring CRO?

The cheapest writer is rarely the right one here, because the cost of a poorly argued package is a clinical hold or an information request that stalls your trial for months. Weight regulatory track record and submission experience over headline rate. Score two or three candidates against the same scope (the same module list, the same target submission date, the same modality) so you are comparing the same work, not three different definitions of it.

A few questions separate a real partner from a vendor who will hand you a formatted document and walk away. Ask how many INDs the team has actually filed, in your modality, and how many cleared the 30-day review without a hold. Ask who writes Module 2 and whether that person has a nonclinical background or is templating from yours. Ask whether they do the eCTD publishing in-house or subcontract it, because a publishing handoff is a common source of last-week chaos.

  • Quality and GxP status: a documented regulatory quality system, version control and review workflows, and writers trained on current ICH and FDA guidance, not a freelancer with a template.
  • Regulatory track record: number of INDs filed and cleared without a clinical hold, named division experience, and references you can actually call in your therapeutic area.
  • Capacity and lead time: a realistic authoring timeline (typically several weeks from final data to a submission-ready package), confirmed writer availability, and honesty about what slips when a study report lands late.
  • Modality and indication fit: experience with your molecule class (small molecule, monoclonal antibody, ADC, oligonucleotide, cell or gene therapy), since the safety argument and species rationale differ sharply by modality.
  • Region and regulatory pathway: FDA experience for a US IND, plus the ability to adapt the same CTD core for an EMA CTA or other regions if your program is multinational.
  • Data quality and source control: how they reconcile inconsistencies across study reports, manage source documents, and keep a clean audit trail back to the underlying data.
  • IP and confidentiality: clear ownership of the authored documents, a tight CDA covering an unannounced target, and defined handling of your proprietary data and the final dossier.

Frequently asked questions

What is the difference between IND authoring and writing the individual study reports?
They are different jobs. Each GLP study (toxicology, safety pharmacology, genotox) produces its own report, usually written by the CRO that ran the study and owned by its study director. IND authoring sits on top of that. It does not generate new data; it integrates the finished reports into the Module 2 summaries, writes the Investigator's Brochure, builds the safety argument linking your NOAEL to the proposed starting dose, and assembles the whole eCTD package for submission. You can use one full-service CRO for both, or a dedicated regulatory writing group for the authoring while specialist labs run the studies.
Does the package have to be filed in eCTD format for an IND?
For most commercial INDs to the FDA, yes. The agency requires electronic submission in eCTD format through the gateway, structured into the Common Technical Document modules. The authoring CRO either publishes the eCTD in-house or works with a publishing vendor, and either way the submission is validated against technical specifications before it goes out. Ask any candidate whether eCTD publishing is in-house or subcontracted, because a handoff between the writers and the publishers is a frequent cause of last-week delays. Some research and individual investigator-initiated INDs have narrower requirements, but plan for eCTD as the default.
How long does IND authoring take?
Plan on several weeks from final, signed study data to a submission-ready package, though tightly run programs compress it by drafting the Module 2 summaries in parallel with the last study reports rather than after them. The honest variable is your data: a clean, complete dataset authors fast, while missing reports, inconsistent numbers, or a late-arriving non-rodent tox report stretch the timeline. The Investigator's Brochure and the integrated summaries are the long poles. Lock the authoring CRO and the document plan early, while the GLP studies are still in-life, so the writing starts the day the data lands instead of weeks later.
Can the same CRO handle the pre-IND meeting and the IND filing?
Often yes, and there is a real advantage to it. The pre-IND meeting is where you align with the FDA division on your development plan, your starting dose rationale, and any open questions about the nonclinical package or trial population. A CRO that drafted the briefing book and sat in that meeting already knows what you agreed and can build the IND to match, which reduces the chance of a mismatch that triggers an information request. If you split the work, make sure the authoring group gets the full pre-IND meeting minutes and any FDA feedback before they start writing.
Who owns the authored documents and my data?
In a well-structured arrangement, you own the final dossier and all the documents the CRO authors for you, and the CRO holds your underlying data only under a confidentiality agreement. Settle this in writing before work starts. Confirm that the IND, the Investigator's Brochure, and the Module 2 summaries are works made for the sponsor, that your proprietary data and the target itself are covered by the CDA (relevant if you have not disclosed the program publicly), and that you receive editable source files, not just locked PDFs, so you can author amendments and future submissions without being tied to one vendor.
What happens if the FDA puts my IND on clinical hold?
An IND goes into effect 30 days after the FDA receives it unless the agency notifies you sooner that you may proceed or places the program on clinical hold under 21 CFR 312.42. A hold means a deficiency, often in the safety data, the proposed dose, the manufacturing information, or the protocol, that has to be resolved before you can dose. A strong authoring CRO reduces hold risk up front with a gap analysis against ICH M3(R2) and FDA guidance, and if a hold does land they draft the complete response that addresses each issue. When you scope the engagement, confirm whether clinical-hold response support is included or a separate change order.

Source IND / Regulatory Package Authoring with one contract

Compare transparent quotes from qualified IND / Regulatory Package Authoring CROs, then contract once. Free for buyers.

Compare quotes